MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in MacroGenics, Inc. (NASDAQ:MGNX) by 7.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 527,185 shares of the biopharmaceutical company’s stock after purchasing an additional 34,420 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.84% of MacroGenics worth $1,713,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new stake in shares of MacroGenics during the 3rd quarter worth approximately $37,000. Sanders Morris Harris LLC acquired a new position in MacroGenics during the fourth quarter worth about $40,000. Intech Investment Management LLC purchased a new stake in shares of MacroGenics in the third quarter valued at approximately $68,000. XML Financial LLC raised its holdings in shares of MacroGenics by 31.6% during the 4th quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 5,569 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in MacroGenics by 104.5% in the 4th quarter. SG Americas Securities LLC now owns 34,399 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 17,577 shares during the last quarter. 96.89% of the stock is currently owned by institutional investors and hedge funds.

MacroGenics Price Performance

Shares of MacroGenics stock opened at $1.26 on Friday. MacroGenics, Inc. has a 12 month low of $1.26 and a 12 month high of $19.54. The stock has a market capitalization of $79.49 million, a price-to-earnings ratio of -0.80 and a beta of 2.12. The firm’s fifty day simple moving average is $2.51 and its 200-day simple moving average is $3.16.

MacroGenics (NASDAQ:MGNX) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $49.40 million during the quarter, compared to analyst estimates of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. Analysts anticipate that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. HC Wainwright reduced their price objective on shares of MacroGenics from $4.00 to $2.00 and set a “neutral” rating on the stock in a report on Tuesday, March 25th. StockNews.com cut shares of MacroGenics from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Nine equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.38.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.